Oakworth Capital’s Neurocrine Biosciences NBIX Stock Holding History

Oakworth Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83.5K	Buy	498 +127	+34%	+$18.8K	﹤0.01%	383
2026 Q1	$48.9K	Sell	371 -2,313	-86%	-$307K	﹤0.01%	450
2025 Q4	$381K	Hold	2,684	–	–	0.02%	166
2025 Q3	$377K	Sell	2,684 -90	-3%	-$12.2K	0.02%	164
2025 Q2	$349K	Hold	2,774	–	–	0.02%	154
2025 Q1	$307K	Hold	2,774	–	–	0.02%	165
2024 Q4	$379K	Buy	+2,774	New	+$343K	0.03%	147

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Aware Super Sydney, Australia $7.06B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Oakworth Capital's NBIX Position: Q2 2026 in Review

Oakworth Capital increased its Neurocrine Biosciences (NBIX) stake by 34% in Q2 2026, buying an estimated $18.8K and bringing the position to 498 shares worth $83.5K. The position accounts for ﹤0.01% of the portfolio, ranked #383.

Oakworth Capital first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $381K in Q4 2025. 243 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Oakworth Capital held 498 shares of Neurocrine Biosciences worth $83.5K as of Q2 2026.
Oakworth Capital bought 127 Neurocrine Biosciences shares in Q2 2026, an estimated $18.8K.
Neurocrine Biosciences made up ﹤0.01% of Oakworth Capital's portfolio in Q2 2026, its #383 holding.
Oakworth Capital first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
Oakworth Capital's Neurocrine Biosciences position peaked at $381K in Q4 2025.
243 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Oakworth Capital's 13F filing for Q2 2026, filed 22 Jul 2026.